ALSO NOTED: Dutch court ruling protects Pfizer's Lipitor; J&J loses bid to dismiss whistleblower suit;

> Pfizer announced that a Dutch court ruled to prevent generics maker Ranbaxy from launching a copycat form of the best-selling Lipitor. Report

> Pfizer has demonstrated once again just how interested it is in biotech with its $195 million deal to buy Encysive. Report

> A federal judge denied Johnson & Johnson's attempt to get a whistleblower suit dismissed; the suit involves charges that J&J's Ortho-McNeil unit offered kickbacks to hospitals that purchased more of its Levaquin antibiotic than a rival med. Report

> Danish drug maker Lifecycle Pharma has launched its cholesterol med Fenoglide in the U.S., marketing it through U.S. partner Sciele Pharma. Release

> India's Aurobindo Pharma is investing $14.7 million in a manufacturing plant in Malta, planning to use it to strengthen its presence in Europe. Report

> The FDA gave its blessing to a new liquid allergy medication, Xyzal, made by UCB and Sanofi-Aventis; the drug's tablet form was approved in May 2007. Report

> An FDA advisory panel agreed Wednesday that GlaxoSmithKline's Rotarix vaccine was safe and effective, recommending the anti-rotavirus shot for agency approval. If approved for sale, Rotarix will compete with Merck's RotaTeq, which has been on the market since 2006. Report

> A Nobel Prize-winning biologist says that researchers are no closer to developing a vaccine against HIV than they were 20 years ago, when the scientific quest began. Report

> Can a vaccine control high blood pressure? Report

> There's growing evidence around the U.S. that the flu jab offers only marginal protection against the seasonal ailment. Report

And Finally... Is this a pharma opportunity? New research in Nature shows new infectious diseases are emerging at a rapid pace. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.